Anaplastic Myeloma: New Insights From Four Case Studies

0
0
0

Anaplastic Myeloma: New Insights From Four Case Studies of a Rare, Aggressive Multiple Myeloma Subtype

Multiple myeloma (MM) is a common blood cancer, but one of its rarest and most aggressive subtypes—anaplastic myeloma (AM)—remains poorly understood. Only 2.6% of MM patients develop AM, and since its first report in 1983, most research has been limited to case studies. Now, a 2020 analysis of four AM patients offers new clues about this devastating disease.

AM includes anaplastic multiple myeloma and anaplastic plasmacytoma, characterized by abnormal plasma cells that grow rapidly and resist standard treatments. Patients often face poor outcomes, but the lack of large studies has left gaps in diagnosis and care. To fill these gaps, researchers from Shandong Provincial Hospital Affiliated to Shandong First Medical University and Affiliated Hospital of Qingdao University analyzed clinical and histopathological data from four AM patients treated between 2015 and 2019. Their findings, published in the Chinese Medical Journal, shed light on AM’s unique features and potential treatment paths.

Who Does AM Affect?

All four patients in the study were under 60 years old—younger than the average MM patient. They shared key clinical features:

  • Anemia: Low hemoglobin levels (78–99 g/L) caused fatigue and weakness.
  • Low Immunoglobulins (Ig): Reduced antibody levels left them vulnerable to infections.
  • Extramedullary Masses: Tumors outside the bone marrow, including intraspinal masses (causing paralysis), intraperitoneal masses, and a skull mass.
  • Osteolytic Lesions: Severe bone damage visible on scans, a hallmark of MM but particularly aggressive in AM.

What Makes AM Cells Unique?

Pathological tests revealed distinct traits of AM cells:

  • Morphology: Odd-shaped (“pleomorphic”) and multinucleated cells with vacuolated nuclei and prominent nucleoli. Some resembled sarcoma or lymphoma cells, raising misdiagnosis risks.
  • Immunophenotype: AM cells consistently expressed plasma cell markers (CD38+, CD138+, MUM1+) but lacked lymphocyte markers (CD20-, CD3-, CD79a-). They also showed restricted light chain expression (either kappa or lambda), a sign of clonal growth.
  • Genetic Abnormalities: Fluorescence in situ hybridization (FISH) and karyotyping found high-risk changes like 1q21 gain (linked to poor MM outcomes), deletion of 13q14.3, and TP53 deletion (a driver of treatment resistance).

The Challenge of Diagnosis

Distinguishing AM from plasmablastic lymphoma (PBL)—a similar B-cell cancer—is critical. Both diseases involve fast-growing abnormal cells, but PBL is often tied to HIV or immunodeficiency. AM patients typically have:

  • M-protein (abnormal antibodies) in blood/urine.
  • Osteolytic bone lesions.
  • No history of severe immunodeficiency.

Immunohistochemistry is key: AM cells retain plasma cell markers (CD38, CD138), while PBL cells often lose these markers.

Treatment: Few Options, Some Hope

AM resists most standard MM therapies. In the study:

  • Novel Agents: Bortezomib (a proteasome inhibitor) and thalidomide (an immunomodulator)—mainstays of MM care—failed for three patients.
  • Intensified Chemotherapy: The V-DECP regimen (bortezomib + cisplatin, cyclophosphamide, etoposide, dexamethasone) led to partial remission (PR) in two patients. One patient who received V-DECP plus thalidomide-VAD survived over nine months—longer than the others.

The authors suggest combining novel agents with high-dose chemotherapy may improve responses. They also note immunotherapies like CAR-T cell therapy or monoclonal antibodies could offer future hope.

What This Means for Patients

While the study is small, it highlights critical takeaways:

  • Early Recognition: AM should be considered in young MM patients with rapid extramedullary growth, low Ig levels, and treatment resistance.
  • Personalized Care: Genetic testing (e.g., FISH for TP53 or 1q21) can guide therapy choices.
  • Need for More Research: Larger studies are essential to confirm findings and develop targeted treatments.

AM remains a devastating disease, but this 2020 study is a step forward. For patients and doctors, the message is clear: AM is not just a “worse” form of MM—it’s a unique condition that requires tailored approaches. As more data emerges, there’s hope for better outcomes.

Huang JX, Meng FJ, Feng XQ, Lyu X, Wang X. Clinical and histopathological analyses of anaplastic myeloma. Chinese Medical Journal. 2020;133(13):1614-1616. doi.org/10.1097/CM9.0000000000000902

Was this helpful?

0 / 0